Nutriband Inc. entered into an amended three-year $5,000,000 credit line facility on June 1, 2026. This agreement replaces a previous $5,000,000 facility that was set to expire on July 13, 2026. Drawdowns under the new facility carry an interest rate of 7% per annum and do not allow the lender to convert outstanding amounts into common stock. The financing is intended to support the FDA approval process and commercial scale manufacturing of AVERSA™ Fentanyl, the company's patented abuse-deterrent fentanyl transdermal system. Nutriband Inc. is a healthcare company developing abuse-deterrent transdermal delivery systems.